Candio-Hermal

Nystatin

Treatment option: Infection, Oral Cavity

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Candio-Hermal

Property	Description
Active ingredient	Nystatin (INN)
Form	Cream, Softpaste, Ointment, Oral Suspension
Pharmacological class	Antifungal Agent (Polyene Macrolide)
Common use	Localized yeast and fungal infections
Origin	Derived from the bacterium Streptomyces noursei

Candio-Hermal: An Antifungal Agent and its Classification

Candio-Hermal is a specialized antifungal agent medication designated for the localized treatment of infections caused by yeasts, primarily those of the Candida genus. Its identity is defined by its sole active component, the substance Nystatin, classifying it as a monopreparation.

Nystatin belongs to the Polyene Macrolide group within the broader Antifungal Agent pharmacological class. This active substance is a naturally derived antibiotic, specifically produced by the bacterium Streptomyces noursei, and is used for its targeted action against fungal pathogens. Due to its very poor absorption into the bloodstream, Nystatin's efficacy is limited to the site of application and is not indicated for the treatment of deep, systemic mycoses. The established property of Nystatin as a local treatment is clinically recognized for its direct, non-systemic approach to infection control.

Composition and Available Pharmaceutical Forms

The core composition of Candio-Hermal features Nystatin alongside different inactive bases to facilitate targeted delivery. To address infections across various localized sites—a distinctive feature of the product—the medication is manufactured in multiple pharmaceutical preparations, including Cream, Softpaste (or Paste), Ointment (Salbe), and an Oral Suspension (Mundgel).

These physical forms define the Route of administration, which is either Topical for cutaneous and mucosal surfaces, or Oral for localized action within the gastrointestinal tract. Nystatin's primary role is to eliminate fungal organisms directly at the point of application, whether on the skin or mucous membranes. The availability of different forms allows for targeted treatment, such as using the Softpaste for irritated skin or the Oral Suspension for oral thrush.

Primary Purpose and Fungicidal/Fungistatic Action

The general purpose of Candio-Hermal is to control and eliminate yeast overgrowth by directly interfering with the structural components of the fungal cell membrane. The active ingredient executes this by binding to sterols within the yeast cell wall. This high-level action is known to be either fungistatic—halting the proliferation and growth of the organism—or fungicidal—actively destroying the fungal cells. By ensuring this targeted disruption, the medication reliably stops the infectious organism from spreading, which is essential for resolving the underlying cause of the localized infection.

Regulatory References

Nystatin - LiverTox (NIH)

What side effects are possible with Candio-Hermal?

Possible Side Effects and Safety Information

The safety profile of Candio-Hermal (Nystatin) is primarily defined by the drug’s poor absorption, resulting in adverse reactions that are largely localized to the site of application.

Adverse Reactions by Organ System

The most commonly documented adverse effects affect the areas directly exposed to the medicine. The official labels classify side effects across two main areas:

Skin and Subcutaneous Tissue Disorders: When using the cream or paste, reported effects include local irritation, a burning sensation, rash, and pruritus (itching).
Gastrointestinal Disorders: With the oral suspension, nausea, vomiting, diarrhea, and stomach pain are documented.

Serious and Rare Adverse Reactions

Although Nystatin is generally confined to local action, official regulatory documents note the potential for severe, immune-mediated reactions, which are rarely reported.

Classification	Serious Adverse Reactions
Very Rarely Reported	Stevens-Johnson syndrome (SJS)
Rarely Reported	Anaphylactoid reaction, Angioedema, Urticaria (hives)

Treatment must be discontinued if symptoms of sensitization or irritation occur. A history of hypersensitivity to Nystatin or any component of the formulation is a formal restriction for use.

Population-Specific Safety Notes

The medicine is explicitly noted as not effective for systemic (deep) mycoses. Regarding specific populations, official safety notes indicate that Nystatin should be used in pregnancy only if clearly needed, and that caution should be exercised when administered to a nursing mother. Additionally, patients with renal insufficiency may occasionally show minor systemic absorption with the oral form.

Overdose and Emergency Response

Overdose Scope: Officially Documented Manifestations

Property	Official Regulatory Documentation
Documented Presentations	Nausea, Gastrointestinal upset, or Gastrointestinal disturbances
Physiological Systems Affected	Gastrointestinal system
Dose-Related Factors	Occurs following oral doses in excess of five million units daily
Severity Classification	No reports of serious toxic effects following overdosage

When to Seek Urgent Medical Help

In case of accidental overdose, regulatory labeling mandates that individuals seek professional assistance or contact a Poison Control Center immediately.

Official Overdose Statements:

The documented clinical manifestations of overdose are non-serious and limited to gastrointestinal manifestations, consistent with Nystatin's established property of insignificant gastrointestinal absorption.
Management procedures officially described in regulatory documents include symptomatic therapy, general supportive measures, and procedures such as gastric lavage.
There is no specific antidote listed for Nystatin overdosage.
A population-specific note highlights that patients with renal insufficiency receiving oral therapy may occasionally reach significant plasma concentrations of nystatin, which is a factor considered in regulatory overdose analysis.

Connection to the Overall Overdose Profile

Official regulatory documents define the overdose profile as non-life-threatening due to the minimal systemic absorption of the active ingredient. The profile focuses on localized, non-serious gastrointestinal effects. Nonetheless, official guidance strictly requires the immediate action of seeking professional assistance upon suspected accidental overdose to ensure appropriate management and observation.

Therapeutic Uses of Candio-Hermal

What Candio-Hermal Treats: Main Uses and Benefits

This medication is used in situations involving certain distressing symptoms caused by fungal overgrowth. It is applicable within clinical settings that involve acute or disruptive symptom patterns, primarily those linked to superficial Candida species infections.

It is generally considered relevant in conditions characterized by periods of heightened symptoms such as oral thrush, non-invasive gastrointestinal candidiasis, cutaneous candidiasis (e.g., in skin folds), and diaper rash complicated by fungal components. The medication is applied in addressing symptom clusters that may become intense or disruptive, including soreness, inflammation, pruritus (itching), burning, and visible redness.

The medication may assist with symptomatic relief that helps patients cope more steadily when symptoms interfere with routine activities. For example:

“The goal is to provide supportive symptomatic relief to mitigate acute, distressing manifestations and support a return to comfort.”

This action supports the patient during difficult episodes by easing distress and contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Inflammatory Discomfort

Candio-Hermal is applied across domains where additional symptomatic support is needed to address discomfort stemming from localized yeast infection, supporting the patient in managing acute inflammation and pain in sensitive skin and mucosal areas.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Candio-Hermal — Official Regulatory Information

Eligibility scope

Populations for whom use is allowed (as stated in label): The medicine is officially permitted for use across all age groups—including neonates, infants, children, adults, and older adults—when treating localized fungal infections (e.g., oral or cutaneous candidiasis).
Populations for whom use is contraindicated: Use is strictly prohibited in individuals with known hypersensitivity to Nystatin or any non-active component of the specific formulation. The medicine must not be used to treat systemic or deep-seated fungal infections, as the drug's poor absorption prevents internal therapeutic action.
Pregnancy and lactation eligibility status: Use during pregnancy is documented as conditional, allowed only if clearly needed (often classified as Category C). Use in nursing mothers requires caution, though systemic absorption is minimal.
Condition-specific eligibility rules: Due to the drug's non-systemic nature, official labeling mandates no explicit restrictions based on severe renal or hepatic impairment. However, the oral suspension is contraindicated for patients with specific rare hereditary sugar-digestion disorders.

Connection to the overall eligibility profile: Official regulatory documents define eligibility primarily through two absolute exclusions: hypersensitivity to the drug and the type of infection (only localized infections are permitted). All age groups are broadly permitted to use the drug for its labeled indications, with conditional use applied during pregnancy and lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Candio-Hermal is fundamentally characterized by the active substance, Nystatin, having minimal systemic absorption. Official regulatory documents state that Nystatin is not significantly absorbed from the gastrointestinal tract or mucosa, and it is not metabolized in the bloodstream. This non-systemic nature ensures that Candio-Hermal is not documented to cause clinically relevant pharmacokinetic interactions affecting the systemic clearance or exposure of other medicines via CYP enzymes or drug transporter proteins.

Documented Local Interactions and Restrictions

Type of Interaction	Interacting Substance/Condition	Regulatory Statement
Physical Inactivation	Allogeneic cultured biological products (topical/mucosal)	Co-administration is listed as a Contraindicated Combination due to the risk of Nystatin causing physical degradation.
Local Antagonism	Live Therapeutic Yeasts (e.g., Saccharomyces boulardii)	The fungicidal action may decrease the therapeutic effect of the co-administered yeast. This combination is classified as requiring avoidance.
Administration Timing	Food or Drink (Oral Suspension)	A mandatory time separation (e.g., 20–30 minutes) is required following administration to ensure sufficient contact time with the infected tissue.

The documented warnings and restrictions pertain exclusively to local effects. The official interaction profile is thus structured by the lack of systemic exposure, directing all constraints toward local incompatibility and the timing requirement to preserve contact duration at the site of infection. No population-specific interaction considerations are documented.

Mechanism of Action

The mechanism of Candio-Hermal is defined by localized structural disruption of fungal organisms, driven by its active ingredient, Nystatin, a polyene macrolide.

Selective Molecular Targeting and Membrane Disruption

This mechanism initiates through specific molecular recognition. The drug acts by binding directly to ergosterol, the unique sterol molecule found exclusively in the fungal cell membrane, ensuring selective interaction with the fungal membrane. This targeted binding subsequently leads to the aggregation of Nystatin molecules and the formation of hydrophilic aqueous pores across the cell membrane, which results in rapid compromise of the cell's structural integrity.

Cascade to Fungal Cell Homeostasis Collapse

This structural failure triggers the rapid cellular consequences that lead to the final mechanism of action. The creation of membrane pores causes the uncontrolled efflux of essential electrolytes and vital intracellular contents. This immediate loss of material and dissipation of the electrochemical gradient disrupts the fungal cell's internal stability, leading to metabolic failure. This results in the final physiological effect: the fungicidal (cell-killing) or fungistatic (growth-stopping) action that causes the cessation of fungal organism proliferation.

Dosage and Administration Information

How to Use Candio-Hermal: Official Administration Guidelines

The administration of Candio-Hermal, which contains the active ingredient Nystatin, is defined by strict instructions that ensure its non-systemic, localized action against fungal infections. Usage is categorized by its two approved routes: Oral (Suspension) for the mouth and gastrointestinal tract, and Topical (Cream/Ointment/Paste) for skin and mucocutaneous areas.

Administration Protocol

The official dosing and administration regimens for Nystatin are standardized for clinical application.

Administration Aspect	Protocol
Route & Form	Oral Suspension (100,000 units/mL) or Topical Forms (100,000 units/g).
Frequency	Oral Suspension is typically administered four times daily (QID). Topical forms are generally applied twice daily (BID).
Adult Dosing (Oral)	4 to 6 mL (400,000 to 600,000 units) per dose.
Pediatric Dosing (Oral)	Infants are typically dosed at 2 mL (200,000 units) QID; for premature infants, the dose is 1 mL (100,000 units) QID.

Procedural Technique and Duration

Proper use is critical for localized efficacy. The oral suspension must be shaken well before measurement. For treating oral candidiasis, the medication is divided, with one half placed in each side of the mouth, and must be retained in the mouth as long as possible before swallowing to ensure contact with the affected mucosa. Topical forms are applied liberally to the infected area and are strictly not for ophthalmic use.

Treatment duration is based on clinical criteria, not a fixed period. Oral therapy should continue for at least 48 hours after symptoms have disappeared, while topical therapy is maintained until complete clinical healing is achieved, which is essential to prevent recurrence.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Candio-Hermal

Evidence for Use in Oral Candidiasis

The core evidence for Nystatin was evaluated for use in infections such as oral thrush, primarily derived from Randomized Controlled Trials (RCTs) and Systematic Reviews. Research has examined changes in symptoms in diverse populations, including infants, children, and adults. The main outcomes research examined relate to both Clinical Cure (resolution of visible symptoms and lesions) and Mycological Cure (the measure of fungal load reduction or absence).

Findings describe patterns observed in these short-term studies where measurements of Clinical Cure and fungal clearance were tracked. The data show patterns related to measured outcomes when Nystatin was compared to an inactive substance in trials involving immunocompetent patients. However, research exploring its effectiveness compared to newer, systemic antifungal medications, particularly in immunocompromised patient groups, has yielded findings with varying results.

Evidence for Use in Cutaneous Candidiasis

The evidence for Nystatin was evaluated for use in localized fungal infections of the skin, such as in skin folds or diaper rash complicated by yeast, in clinical studies and RCTs. The studies explored outcomes linked to inflammatory states, focusing on measuring Clinical Resolution (the clearing of redness, burning, and itching) and achieving fungal clearance from the skin surface. Research focuses on short-term responses, typically lasting one to two weeks.

Evidence in High-Risk and Pediatric Populations

Nystatin was studied for its use in special populations, particularly in a prophylactic role (preventative use) in Very Low Birth Weight (VLBW) preterm neonates. The studies observed how the drug affected the Fungal Colonization Rate (the presence of yeast on cultures) and also monitored the more serious outcome of Systemic Fungal Infection (SFI) incidence. Research highlights that changes measured during the study period showed patterns related to colonization outcomes in infants. Data for long-term effects on these infants are limited.

Research Gaps and Unanswered Questions

The evidence quality varies across studies, and data on long-term effects are limited for any indication. Follow-up durations are typically short, and comparative evidence is lacking against all classes of newer antifungals in certain patient groups. Research continues to explore these patterns, and evidence highlights what is known — and what is still uncertain — about the full scope of Nystatin's therapeutic profile.

Frequently Asked Questions (FAQ)

Common questions about Candio-Hermal (FAQ)

Q: How quickly does Candio-Hermal typically start to show its expected effects?

Clinical studies have observed symptomatic improvement within the first few days of beginning consistent application. However, regulatory guidance indicates that treatment continuation is necessary to achieve clinical resolution. The medication is generally recommended to be continued until the clinical signs of the infection have fully resolved, and in some cases, for a set period afterward.

Q: What should a patient expect if they stop using Candio-Hermal before the prescribed time?

Regulatory documents state that one of the risks of stopping treatment early is the recurrence or return of the fungal infection. Therefore, regulatory guidance advises that the full duration of therapy is necessary, even if symptoms appear to have disappeared before completion.

Q: Can Candio-Hermal cause effects in parts of the body other than where it is applied?

According to official product information, the active ingredient Nystatin is minimally absorbed from the skin or gastrointestinal tract. Because of this poor absorption, the effects of the medicine are largely localized to the area of application. Due to minimal absorption, clinically relevant systemic (body-wide) effects are not documented or expected, and adverse reactions are primarily confined to the treatment area.

Q: Is a mild burning sensation normal when first applying Candio-Hermal?

Official regulatory labels list a burning sensation as a possible local side effect when using the topical form. If this sensation becomes severe or if any sign of sensitization or increased irritation occurs, official regulatory documents state that the medication should be discontinued.

Q: Does having a pre-existing liver condition affect eligibility for Candio-Hermal?

Due to the minimal systemic absorption of the active ingredient, regulatory documents do not list explicit restrictions or contraindications regarding the use of Candio-Hermal in patients with pre-existing hepatic (liver) impairment.

Q: What is the difference between a fungistatic and a fungicidal drug, in simple terms?

The mechanism of action is described as both fungistatic and fungicidal. Fungistatic means the medicine stops the fungal organism from growing and proliferating. Fungicidal means the medicine actively works to destroy the fungal cells themselves.

Q: Are there any specific populations where Candio-Hermal is described as less effective?

Research evidence has examined Candio-Hermal's efficacy compared to newer systemic antifungal medications, particularly in immunocompromised patient populations. Official documents note that studies comparing it to other antifungals in immunocompromised groups have produced results that vary.

Q: Is Candio-Hermal a steroid-containing medication?

The monotherapy versions of Candio-Hermal list Nystatin as the sole active ingredient, which is an antifungal agent. The official composition does not list a steroid as an active ingredient (corticosteroid).

Q: Can Candio-Hermal interact with common supplements like vitamin D or zinc?

Official regulatory documents do not specify clinically relevant systemic interactions with common supplements, aligning with the fact that Nystatin has minimal absorption into the bloodstream. This means the medicine does not significantly affect the systemic exposure of other substances.

Q: Is there a known interaction between Candio-Hermal and alcohol consumption?

Official regulatory labels and warnings do not contain a specific statement regarding an interaction with alcohol consumption while using Candio-Hermal.

Q: Is there any research evidence concerning the use of Candio-Hermal in elderly patients?

The medicine is included in the eligibility for the elderly population. While specific comparative clinical data for this age group may be limited, official labels state that the drug is not generally anticipated to cause different side effects or safety problems in older adults compared to younger adults.

Q: Is it true that resistance to Candio-Hermal can develop over time?

Official microbiology information indicates that resistance to Nystatin is typically not observed to develop during standard therapy. However, research has noted the potential for some specific strains of the Candida genus to become less susceptible upon repeated or long-term treatment.

Q: Is it necessary to avoid sunlight exposure while using Candio-Hermal?

Official patient information and warnings sections do not specify photosensitivity or the need to avoid sunlight exposure as a required precaution while using this medicine.

Q: Does Candio-Hermal have a known effect on the user's immune system?

Official documents describe the medicine's mechanism as localized: it works by disrupting fungal cell membranes directly at the site of infection. Systemic immune modulation (changing the body’s overall immune response) is not documented as a known direct action or side effect of the medicine.

Q: Can Candio-Hermal affect mental health, such as causing anxiety or mood changes?

Adverse events related to mental health, such as anxiety or mood changes, are not specified among the commonly reported or rare systemic side effects in official regulatory labels for Candio-Hermal.

Q: Can the medication stain clothes or skin?

Official patient information and warnings sections do not include a specific statement regarding staining of the skin or clothing.

Q: Does Candio-Hermal require a prescription, or is it available over the counter?

According to regulatory product information, Candio-Hermal (Nystatin monotherapy) is primarily classified as a prescription-only medicine (Rx Only) for its labeled indications.

Q: Does official guidance recommend a patient should wear certain types of clothing when using Candio-Hermal?

When using the topical forms of Candio-Hermal on areas like the groin or diaper area, official guidance addresses the practice of wearing loose-fitting clothing or avoiding tight dressings/diapers. This is addressed because excessive covering can increase the risk of local side effects.

Q: What is the potential impact of Candio-Hermal on certain lab test results?

Due to the minimal systemic absorption of the active ingredient, Nystatin, the medicine is not generally anticipated to interfere with systemic laboratory test results.

Q: Does using excessive amounts of the product affect its performance or safety?

Official warnings address the practice of applying excessive amounts of the product or covering the treated area with occlusive dressings (such as tight bandages or plastic). Such application is addressed as it may increase the risk of local side effects, such as irritation or rash.

How should Candio-Hermal be stored and disposed of?

Official Storage and Disposal Requirements

Storing Candio-Hermal correctly is essential for maintaining its effectiveness, as defined by regulatory labeling.

Requirement Area	Official Labeling Statements
Temperature & Environment	Store within the specified temperature range (e.g., Do not store above 30°C or 2 C–8 C). Protect from freezing and excessive heat.
Handling & Packaging	Keep the medicine in the original container to protect it from light and moisture. The container must remain tightly closed.
Child Safety	Keep out of the sight and reach of children at all times.
Disposal	Do not dispose of unused or expired Candio-Hermal in household waste or wastewater. Return the product to a designated collection point, such as a pharmacy, following local pharmaceutical waste regulations.